Links

 

Funding

Current Funding:

NIH R21 Grant (Rubin, PI)
12/1/08-11/30/10
Non-Invasive Ultrasound Elasticity Imaging (UEI) in Crohns Disease
Role: Co-Investigator
This study will investigate the potential of UEI to radically improve the diagnosis and timely management of intestinal fibrosis in Crohns Disease.

NIH K08 Grant 2 1K08DK080172-01 (PI: Higgins)
Project title:Mechanisms and Prevention of TGF-Beta-Induced Intestinal Fibrosis
Project Director: Peter Higgins, M.D., Ph.D., M.Sc.
Entire period of support: 2/1/08-1/31/11
The long-term research goal is to elucidate the mechanisms of TGFB1-driven intestinal fibrosis and to use this information to target anti-fibrotic therapies that can prevent or reverse intestinal fibrosis.

Genentech Investigator-Initiated Grant (PI: Higgins)
Project title: Development of Patient Reported Outcome Measures for Ulcerative Colitis and Crohns Disease
Project Director: Peter Higgins, M.D., Ph.D., M.Sc.
Entire period of support: 9/1/09-12/31/10
Total Direct Costs: $794,305

Centocor anti-IL12/23 UstekinumabStudy (PI: Higgins)
A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety, and intravenous induction of response and subcutaneous maintenance therapy with ustekinumab in patients with moderately to severely active Crohns Disease who have failed a previous anti-TNF therapy (including remicade, humira, or cimzia)

Completed Funding:

NIH T32 Medical Scientist Training Program, GM07171
National Institutes of Health
Training Program Director: Salvatore Pizzo, M.D., Ph.D.
Duke University
Entire period of support: 8/1987-5/1998

NIH T32 Training for Research in Gastroenterology, DK 007367-24
University of Michigan Gastroenterology Division
Project Director: Chung Owyang, M.D.
Entire period of support: 7/1/2002-6/30/2003

NIH T32 Program in GI Epidemiology and Outcomes, DK62708-01
National Institutes of Health
Project Director: Philip Schoenfeld, M.D., M.S., M.Ed.

NIH K30 Award for Clinical Research, HL004108
National Institutes of Health
Project Director: David Schteingart, M.D.
Entire period of support: 7/2003-6/2005

Munn Idea Awards in Colon Cancer Research
University of Michigan Cancer Center
Project title: Multi-agent Chemoprevention of Colon Polyps and Colorectal Cancer
Source of support: University of Michigan Cancer Center
Project Co-Directors: Peter Higgins, M.D., Ph.D.,
Philip Schoenfeld, M.D., M.S., M.Ed.,
Steven Gruber, M.D., M.P.H.
Entire period of support: 3/1/03-8/30/05

GCRC Research Funding
Project title:
Lipitor In the Treatment of Ulcerative Colitis
Source of support: University of Michigan GCRC [GCRC Protocol #1884]
Project Co-Directors: Peter Higgins, M.D., Ph.D., and Ellen Zimmermann, M.D.
Entire period of support: 5/1/02-12/31/05

AGA Centocor Excellence in IBD Clinical Research Award
Detection of Enteric Fibrosis in Crohns Disease
American Gastroenterological Association
Project Director: Peter Higgins, M.D., Ph.D.
Entire period of support: 7/2004-6/2006

NIH K12 Award for Clinical Research, RR017607-01
National Institutes of Health
Project Director: David Schteingart, M.D.
Entire period of support: 1/1/2004-12/31/2006 

Crohns and Colitis Foundation of America Senior Research Award
Project title:
Development of a Novel Noninvasive Measure of Ulcerative Colitis
Project Director: Peter Higgins, M.D., Ph.D., M.Sc.
Entire period of support: 2/1/06-1/31/09
This study will rigorously establish a valid basis for the noninvasive assessment of the many new therapies being developed for ulcerative colitis so that the best therapies will be identified, developed, and made available to patients.

Otsuka Adacolumn Clinical Trials 205, 206, 207, 208
Adacolumn Apheresis for Ulcerative Colitis and Crohns Disease
Site PI: Peter Higgins, M.D., Ph.D.
Entire period of support: 8/1/05-12/31/07

ASGE Endoscopic Research Grant
Project title: Sheathed vs. Standard Forceps: Does it matter for obtaining uncontaminated biopsy specimens of microbiota from the terminal ileum?
Project Director: Peter Higgins, M.D., Ph.D., M.Sc.
This study will test the hypothesis that biopsy specimens obtained with standard forceps are more likely to be contaminated with colonic flora and stool, and not represent the true bacterial flora from the site where the specimen is obtained in comparison to sheathed biopsy forceps.

Novartis Pharmaceuticals anti-IL17 Study (Higgins)
3/24/08-12/31/09
A multicenter, randomized, double-blind, placebo-controlled, parallel-group, proof-of-concept study to assess the efficacy, safety, and tolerability of two single iv infusions of AIN457A 10 mg/kg in patients with moderately to severely active Crohns Diseas.